Evidence map›Paper›PMID 24291270›Full record

ReviewJournal of the American College of Cardiology2014

Pre-clinical diastolic dysfunction.

Siu-Hin Wan, Mark W Vogel, Horng H Chen

Abstract readReview
In one paragraph

Review in Journal of the American College of Cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Diagnostic Tests for Stage B Heart Failure.Current cardiology reports · 2026
    Review
  11. Article
  12. Low and High Pressor Doses of Ang II Lead to Two Distinct Phenotypes of Hypertensive Heart Disease in Mice.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026
    Article
  13. Article
  14. Observational
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Siu-Hin WanDepartment of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota.
Mark W VogelDivision of Cardiovascular Diseases, Washington University, St. Louis, Missouri.
Horng H ChenDivision of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota. Electronic address: chen.horng@mayo.edu.

Funding

Recruitment and Phenotyping CoreP01HL076611 · NHLBI · MAYO CLINIC ROCHESTER · PI BURNETT, JOHN C · 2005 to 2015
$19.6M
Human Cardiorenal SyndromeR01HL084155 · NHLBI · MAYO CLINIC ROCHESTER · PI HORNG H CHEN · 2009 to 2026
$5.5M
NHLBI NIH HHS P01 HL076611NHLBI NIH HHS P01 HL 76611NHLBI NIH HHS R01 HL084155NHLBI NIH HHS R01 HL-84155
6 · The paper itself

Abstract

Pre-clinical diastolic dysfunction (PDD) has been broadly defined as left ventricular diastolic dysfunction without the diagnosis of congestive heart failure (HF) and with normal systolic function. PDD is an entity that remains poorly understood, yet has definite clinical significance. Although few original studies have focused on PDD, it has been shown that PDD is prevalent, and that there is a clear progression from PDD to symptomatic HF including dyspnea, edema, and fatigue. In diabetic patients and in patients with coronary artery disease or hypertension, it has been shown that patients with PDD have a significantly higher risk of progression to heart failure and death compared with patients without PDD. Because of these findings and the increasing prevalence of the heart failure epidemic, it is clear that an understanding of PDD is essential to decreasing patients' morbidity and mortality. This review will focus on what is known concerning pre-clinical diastolic dysfunction, including definitions, staging, epidemiology, pathophysiology, and the natural history of the disease. In addition, given the paucity of trials focused on PDD treatment, studies targeting risk factors associated with the development of PDD and therapeutic trials for heart failure with preserved ejection fraction will be reviewed.

Indexed as

Stroke VolumeVentricular Dysfunction, LeftDiastoleDisease ProgressionEchocardiographyGlobal HealthHeart FailureHeart VentriclesHumansPrevalencePrognosisRisk FactorsBNPB-type natriuretic peptidechronic obstructive pulmonary diseaseCOPDDDdiastolic dysfunctionechocardiographyEFejection fractionheart failureheart failure epidemiologyheart failure treatmentheart failure with preserved ejection fractionheart failure with reduced ejection fractionHFHFpEFHFrEFleft ventricularleft ventricular hypertrophyLVLVHN-terminal pro–B-type natriuretic peptideNT-proBNPPDDpre-clinical diastolic dysfunctionSDsystolic dysfunction

Identifiers

PMID24291270
PMCPMC3934927

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.